Market Overview

Novavax Is Working On A Wuhan Coronavirus Vaccine Candidate As First US Case Emerges

Share:
Novavax Is Working On A Wuhan Coronavirus Vaccine Candidate As First US Case Emerges

Novavax, Inc. (NASDAQ: NVAX) said Tuesday afternoon it has initiated development of a vaccine candidate for the Wuhan-version of the coronavirus that has spread from China to other Asian nations and on Tuesday was confirmed to have infected at least one person in the United States.

Novavax shares surged about 60% on Tuesday following reports of the coronavirus outbreak. The company said it has extensive history working with coronaviruses and developing vaccine candidates, including its work on the MERS and SARS coronaviruses.

"Using Novavax’ recombinant nanoparticle vaccine technology, the company expects to develop a vaccine candidate from the genetic sequence of the Wuhan coronavirus," the company said in a statement.

Novavax would also utilize its proprietary Matrix-M adjuvant to potentially provide additional immune response.

What We Know About The Coronavirus Outbreak

The newly-identified coronarvirus emerged in a seafood and poultry market in the Chinese city of Wuhan and has infected more than 300 people, including six who have died, Chinese officials said. The virus has already spread to Beijing and Shanghai, as well as a other Asian nations, including Japan and South Korea.

U.S. health officials confirmed that a man in Washington State who had recently been in the Wuhan area has the virus and is very sick.

Shares of Novavax were up 58.99% on Tuesday afternoon, trading at $9.13.

Related Links:

4 Vaccine Stocks Making Big Moves Amid Coronavirus Outbreak

What You Need To Know About The Coronavirus

Posted-In: coronavirus infectious diseases VaccinesBiotech News Health Care Top Stories General Best of Benzinga

 

Related Articles (NVAX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com